Here's the latest variant picture for the United States, to early March.
The LP.8.1.* variant has continued to grow steadily to around 44%.
The XEC.* variant continued to fall, down to around 24%.
#COVID19 #USA #XEC #LP_8_1
🧵
Here are the leading US states reporting LP.8.1.*.
Strong growth continued in Illinois to 75%, and there is strong growth also in New York, New Jersey and Pennsylvania to 45-55%.
🧵
For the US from January, the LP.8.1.* variant shows a growth advantage of 3.4% per day (24% per week) over the XEC.* variant, with a crossover in mid-February.
🧵
Among the LP.8.1.* sub-lineages, the first child lineage LP.8.1.1 has been the most successful. Note the NY lineages are the descendants of LP.8.1.1.
🧵
Here's the latest variant picture with a global scope.
The XEC.* variant has continued to decline, down to 34% by early March. Meanwhile the LP.8.1.* variant grew to around 28%.
#COVID19 #Global #XEC #LP_8_1
🧵
The LP.8.1.* variant shows a growth advantage of 2.3% per day (16% per week) over the dominant XEC.* variant. That predicts a crossover in mid-March (the data routinely lags).
🧵
Here are the leading countries reporting LP.8.1.*. It has been most successful in Brazil, at 50-70% frequency. There’s also steady growth in the US, past 40%. That shows it potentially being more successful than the XEC.* variant was, and therefore driving larger waves.
🧵
Here's the latest variant picture for the United Kingdom.
The XEC.* variant remains dominant, but growth has stalled at around 60% frequency.
The LP.8.1.* variant grew somewhat to 19% frequency, but then fell back to finish at around 15%.
#COVID19 #UK #XEC #LP_8_1
🧵
For the UK, the LP.8.1.* variant shows an accelerating growth advantage of 1.6% per day (11% per week) over the dominant XEC.* variant. But any crossover looks distant.
🧵
Here's the latest variant picture for the United States.
The LP.8.1.* variant has continued to grow steadily to around 37%.
The XEC.* variant continued to fall, down to around 28%.
#COVID19 #USA #XEC #LP_8_1
🧵
Here are the leading US states reporting LP.8.1.*. Illinois has reported strong growth to 64%, and there is strong growth also in New York, New Jersey, Minnesota and California to around 40%.
🧵
For the US, the LP.8.1.* variant shows a steady growth advantage of 3% per day (21% per week) over the dominant XEC.* variant, with a crossover in mid-February.
🧵
Here's the latest variant picture for the United States.
The XEC.* variant has been overtaken by the LP.8.1.* variant - growing steadily to around 34%.
There’s a rebound underway among the JN.1.* + FLiRT variants, led by the LB.1.3.1 lineage.
#COVID19 #USA #XEC #LP_8_1
🧵
Here are the leading US states reporting LP.8.1.*. Illinois has reported strong growth to 57%, and there is strong growth also in New York, New Jersey and California to around 40%.
🧵
For the US, the LP.8.1.* variant shows a steady growth advantage of 3.1% per day (22% per week) over the dominant XEC.* variant, with a crossover in mid-February.
🧵
Here's the latest variant picture for the United States.
The XEC.* variant is still dominant, but looks like losing top spot shortly.
The LP.8.1.* variant has been growing steadily – up to around 31% and on track to take over from XEC.*.
#COVID19 #USA #XEC #LP_8_1
🧵
Here are the leading US states reporting LP.8.1.*. Illinois has reported continued strong growth to 70%, and there is strong growth also in New York, New Jersey and California to 30-36%.
🧵
For the US, the LP.8.1.* variant shows a steady growth advantage of 3.2% per day (22% per week) over the dominant XEC.* variant. That predicts a recent crossover (the data routinely lags).
🧵
Here's the latest variant picture with a global scope.
The XEC.* variant has continued to decline, while the LP.8.1.* variant grew steadily to around 22%, overhauling the declining JN.1.* + DeFLuQE variants.
#COVID19 #Global #XEC #LP_8_1
🧵
The LP.8.1.* variant shows a steady growth advantage of 2.2% per day (15% per week) over the dominant XEC.* variant. A crossover looks probable in March.
🧵
Among the LP.8.1.* sub-lineages, the first child lineage LP.8.1.1 has been the most successful. Note the NY lineages are the descendants of LP.8.1.1.
🧵